Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions.

Cunningham CO, Giovanniello A, Li X, Kunins HV, Roose RJ, Sohler NL.

J Subst Abuse Treat. 2011 Jun;40(4):349-56. doi: 10.1016/j.jsat.2010.12.002. Epub 2011 Feb 18.

2.

Home- versus office-based buprenorphine inductions for opioid-dependent patients.

Sohler NL, Li X, Kunins HV, Sacajiu G, Giovanniello A, Whitley S, Cunningham CO.

J Subst Abuse Treat. 2010 Mar;38(2):153-9. doi: 10.1016/j.jsat.2009.08.001. Epub 2009 Oct 3.

3.

Factors associated with complicated buprenorphine inductions.

Whitley SD, Sohler NL, Kunins HV, Giovanniello A, Li X, Sacajiu G, Cunningham CO.

J Subst Abuse Treat. 2010 Jul;39(1):51-7. doi: 10.1016/j.jsat.2010.04.001.

4.

Unobserved "home" induction onto buprenorphine.

Lee JD, Vocci F, Fiellin DA.

J Addict Med. 2014 Sep-Oct;8(5):299-308. doi: 10.1097/ADM.0000000000000059. Review.

PMID:
25254667
5.

Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes.

Cunningham CO, Roose RJ, Starrels JL, Giovanniello A, Sohler NL.

J Addict Med. 2013 Jul-Aug;7(4):287-93. doi: 10.1097/ADM.0b013e31829727b2.

6.
7.

Home buprenorphine/naloxone induction in primary care.

Lee JD, Grossman E, DiRocco D, Gourevitch MN.

J Gen Intern Med. 2009 Feb;24(2):226-32. doi: 10.1007/s11606-008-0866-8. Epub 2008 Dec 17.

8.

A trial of integrated buprenorphine/naloxone and HIV clinical care.

Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA.

Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S184-90.

9.

Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.

Ling W, Casadonte P, Bigelow G, Kampman KM, Patkar A, Bailey GL, Rosenthal RN, Beebe KL.

JAMA. 2010 Oct 13;304(14):1576-83. doi: 10.1001/jama.2010.1427.

PMID:
20940383
10.

Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.

Gunderson EW, Wang XQ, Fiellin DA, Bryan B, Levin FR.

Addict Behav. 2010 May;35(5):537-40. doi: 10.1016/j.addbeh.2010.01.001. Epub 2010 Jan 18.

11.

Office-based management of opioid dependence with buprenorphine: clinical practices and barriers.

Walley AY, Alperen JK, Cheng DM, Botticelli M, Castro-Donlan C, Samet JH, Alford DP.

J Gen Intern Med. 2008 Sep;23(9):1393-8. doi: 10.1007/s11606-008-0686-x.

12.

A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.

Amass L, Pukeleviciene V, Subata E, Almeida AR, Pieri MC, D'Egidio P, Stankova Z, Costa A, Smyth BP, Sakoman S, Wei Y, Strang J.

Addiction. 2012 Jan;107(1):142-51. doi: 10.1111/j.1360-0443.2011.03577.x. Epub 2011 Oct 12.

PMID:
21749526
13.

Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.

Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S.

Ann Fam Med. 2007 Mar-Apr;5(2):146-50.

15.

The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence.

Sullivan LE, Moore BA, O'Connor PG, Barry DT, Chawarski MC, Schottenfeld RS, Fiellin DA.

Am J Addict. 2010 Jan-Feb;19(1):53-8. doi: 10.1111/j.1521-0391.2009.00003.x.

16.

Improving temporal efficiency of outpatient buprenorphine induction.

Gunderson EW, Levin FR, Rombone MM, Vosburg SK, Kleber HD.

Am J Addict. 2011 Sep-Oct;20(5):397-404. doi: 10.1111/j.1521-0391.2011.00153.x. Epub 2011 Jul 18.

17.
18.

Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling.

Kornør H, Waal H, Ali RL.

Drug Alcohol Rev. 2006 Mar;25(2):123-30. Erratum in: Drug Alcohol Rev. 2009 Mar;28(2):217. Dosage error in article text.

PMID:
16627301
19.

Buprenorphine implants and opioid dependence.

Rastegar DA.

JAMA. 2011 Jan 19;305(3):253; author reply 254-5. doi: 10.1001/jama.2010.1988. No abstract available.

PMID:
21245178
20.

Effect of incarceration history on outcomes of primary care office-based buprenorphine/naloxone.

Wang EA, Moore BA, Sullivan LE, Fiellin DA.

J Gen Intern Med. 2010 Jul;25(7):670-4. doi: 10.1007/s11606-010-1306-0. Epub 2010 Mar 6.

Items per page

Supplemental Content

Write to the Help Desk